for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SCYNEXIS Inc

SCYX.OQ

Latest Trade

7.28USD

Change

0.01(+0.14%)

Volume

43,246

Today's Range

7.22

 - 

7.43

52 Week Range

4.24

 - 

10.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.27
Open
7.28
Volume
43,246
3M AVG Volume
13.52
Today's High
7.43
Today's Low
7.22
52 Week High
10.20
52 Week Low
4.24
Shares Out (MIL)
20.62
Market Cap (MIL)
149.93
Forward P/E
-2.67
Dividend (Yield %)
--

Next Event

Q1 2021 SCYNEXIS Inc Earnings Release

Latest Developments

More

SCYNEXIS Reports Fourth Quarter And Full Year 2020 Results

Scynexis Announces Positive Results From Interim Analyses Of Ongoing Phase 3 Studies (Furi And Cares), Demonstrating Oral Ibrexafungerp's Ability To Treat Severe Fungal Infections In The Hospita

Scynexis Says On Feb 19, Entered Into Agreement With Amplity To Support Anticipated Commercialization Of Brexafemme In U.S.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SCYNEXIS Inc

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Industry

Biotechnology & Drugs

Contact Info

1 Evertrust Plz Fl 13

JERSEY CITY, NJ

07302-3051

United States

+1.201.8845485

http://www.scynexis.com/

Executive Leadership

Pamela J. Kirby

Chairman of the Board

Marco Taglietti

President, Chief Executive Officer, Director

Eric S. Francois

Chief Financial Officer

Jim Maffezzoli

Vice President of Sales and Marketing

Nkechi Azie

Vice President - Clinical Development

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.800

2019

-9.600

2020

-5.150

2021(E)

-2.793
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
6.28
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
72.57
LT Debt To Equity (MRQ)
72.57
Return on Investment (TTM)
-90.26
Return on Equity (TTM)
-69.12

Latest News

Latest News

BRIEF-Scynexis Reports First Quarter 2020 Financial Results And Provides Company Update

* SCYNEXIS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Scynexis Inc Files For Offering Of Up To 19.4 Million Shares Of Common Stock By Selling Stockholder - SEC Filing

* SCYNEXIS INC FILES FOR OFFERING OF UP TO 19.4 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text for Eikon: https://bit.ly/3bXPHX1 Further company coverage:

BRIEF-Scynexis Says Ibrexafungerp Was Generally Safe And Well-Tolerated

* SCYNEXIS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS SECOND PIVOTAL PHASE 3 STUDY (VANISH-306) OF ORAL IBREXAFUNGERP FOR THE TREATMENT OF VULVOVAGINAL CANDIDIASIS (VAGINAL YEAST INFECTION)

BRIEF-Scynexis, Aspire Capital Enter $20 Mln Common Stock Purchase Agreement

* SCYNEXIS AND ASPIRE CAPITAL ENTER INTO $20 MILLION COMMON STOCK PURCHASE AGREEMENT

BRIEF-Scynexis Expects Top-Line Data For Phase 3 Candle Study Of Oral Ibrexafungerp In H2 2021

* SCYNEXIS REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-SCYNEXIS Announces Preclinical Data On Ibrexafungerp And Azoles Against Aspergillus Presented At The 9Th Advances Against Aspergillosis And Mucormycosis Conference

* SCYNEXIS ANNOUNCES PRECLINICAL DATA ON IBREXAFUNGERP AND AZOLES AGAINST ASPERGILLUS PRESENTED AT THE 9TH ADVANCES AGAINST ASPERGILLOSIS AND MUCORMYCOSIS CONFERENCE Source text for Eikon: Further company coverage:

BRIEF-Scynexis Completes Patient Enrollment In Study Of Vaginal Yeast Infection Treatment

* SCYNEXIS COMPLETES PATIENT ENROLLMENT AHEAD OF SCHEDULE IN THE SECOND PIVOTAL PHASE 3 STUDY (VANISH-306) OF ORAL IBREXAFUNGERP FOR THE TREATMENT OF VULVOVAGINAL CANDIDIASIS (VAGINAL YEAST INFECTION)

BRIEF-Scynexis Q1 Loss Per Share $0.12

* SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up